TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ondine Biomedical, Inc. ( (GB:OBI) ) has shared an announcement.
Ondine Biomedical’s Steriwave nasal photodisinfection technology was recently featured on CNBC’s Worldwide Exchange, where former Mexican President Vicente Fox highlighted its potential in addressing global antibiotic resistance, particularly in developing nations. The feature underscores Ondine’s leadership in non-antibiotic infection-prevention solutions and aligns with their mission to combat multidrug-resistant infections worldwide. This media attention supports the company’s strategic initiative, Light Against AMR, aimed at deploying affordable, light-based infection control technologies in underserved markets.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies for infection prevention and treatment. The company is recognized for its photodisinfection technology, with a range of investigational products under development. Its nasal photodisinfection system, Steriwave®, is approved in multiple countries and is undergoing clinical trials in the US.
Average Trading Volume: 389,045
Technical Sentiment Signal: Buy
Current Market Cap: £79.05M
Learn more about OBI stock on TipRanks’ Stock Analysis page.